Product Notices
- Caution: If you choose to combine two or more BD Horizon Brilliant™ Dyes in the same multicolor staining cocktail, fluorescent dye interactions may cause staining artifacts without the use of a buffering solution, such as the BD Horizon™ Brilliant Stain Buffer.
The CD8 antibody, clone SK1, is derived from hybridization of mouse NS-1 myeloma cells with spleen cells from BALB/c mice immunized with human peripheral blood T lymphocytes.
The CD8 antibody recognizes the 32-kilodalton (kDa) α-subunit of a disulfide-linked bimolecular complex. The majority of peripheral blood CD8+ T lymphocytes expresses an α/β heterodimer (Mr 32, 30 kDa), while CD8+CD16+ natural killer (NK) lymphocytes and CD8+ T-cell receptor (TCR)-γ/δ+ T lymphocytes express an α/α homodimer (Mr 30 kDa). CD8+TCR-α/β+ T lymphocytes can express either an α/α homodimer or α/β heterodimer. The CD8 antigenic determinant binds to class I major histocompatibility (MHC) molecules, resulting in increased adhesion between the CD8+ T lymphocytes and target cells. Binding of the CD8 antigen to class I MHC molecules enhances the activation of resting T lymphocytes. The CD8 antigen is coupled to a protein tyrosine kinase, p56lck. The CD8:p56lck complex can play a role in T-lymphocyte activation through mediation of the interactions between the CD8 antigen and the CD3/TCR complex.
No Citations are available for this Product
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
Analyte Specific Reagent. Analytical and performance characteristics are not established.
Analyte Specific Reagent. Analytical and performance characteristics are not established.
Documents are subject to revision without notice. Please verify you have the correct revision of the document, and always refer back to BD's eIFU website for the latest and most up to date information.